Auxilium Pharmaceuticals — Deutsche Bank Conference 2013
44 slides from Auxilium Pharmaceuticals's conference presentation, May 29, 2013

Slide 1: Deutsche Bank Conference Corporate Overview and Strategy
Deutsche Bank Conference “Corporate Overview and Strategy” May 29, 2013

Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: our continued profitability for the year; th

Slide 3: Overview of 1Q13 and Recent Events
Overview of 1Q13 and Recent Events Financial / Commercial Total net revenues of $66.2 MM (-10% vs. 1Q12 ) Global Testim® revenue of $45.5 MM (-22% vs. 1Q12) Global XIAFLEX® revenue of $20.7 MM; U.S. XIAFLEX revenue of $12.0MM (-5% vs. 1Q12) Non-GAAP net loss of $2.3 MM vs. non-GAAP net income of $1.

Slide 4: Testim – 1Q13 Commercial Performance
Testim – 1Q13 Commercial Performance TRT Gel Market Dynamics 1Q13 Prescriptions: +11% vs. 1Q12 4Q12 Prescriptions: +27% vs. 4Q11 Continued heavy investments in DTC advertising within the market Testim Performance 1Q13 U.S. net revenue of $45.3MM; -22% vs. 1Q12 ~$3-4 MM destocking of Testim inventori

Slide 5: XIAFLEX – 1Q13 Commercial Performance
XIAFLEX – 1Q13 Commercial Performance XIAFLEX Performance 1Q13 XIAFLEX U.S. net revenues were $12.0MM; -5% vs. 1Q12 1Q13 XIAFLEX ex-U.S. net revenues were $8.8 MM XIAFLEX Commercial Dynamics Increase of 6.5% in vials shipped to physicians in 1Q13 vs. 1Q12 Market share appears to be trending lower in

Slide 6: Actient Transaction – Aligned with Our Core Strategic Objectives
Actient Transaction – Aligned with Our Core Strategic Objectives $585MM in upfront cash and certain contingent consideration Contingency payments of up to $50MM dependent upon achieving certain sales milestones based on future Actient urology sales Warrants to purchase 1.25 MM shares of Auxilium com

Slide 7: Actient Acquisition – A Compelling Strategic Rationale
Actient Acquisition – A Compelling Strategic Rationale Creates a Leading Urology Franchise Diversifies and Balances Product Portfolio Enhances Existing Commercial Efforts Through Combined Sales Force Strong Growth Profile with Expanding Margins Financially Compelling + 6

Slide 8: Actient – Background and Key Product Portfolio
Urology Respiratory Product Name: Indication: COPD & Asthma Seasonal allergic rhinitis Description Methylxanthine Antihistamine / Decongestant 2012 Revenue ($MM) Erectile dysfunction Leading Non-Oral Prostacyclin Product 25 Erectile dysfunction Vacuum System 13 Testosterone deficiency Buccal Adhesiv

Slide 9: Actient – Strong Revenue Growth Profile
Actient – Strong Revenue Growth Profile 17 59 115 $ Millions (1) (1) Source: Actient audited financial statements and supporting ledgers. See slide A5 in the Appendix to this presentation for a detailed explanation of, and cautionary statements regarding, the source of the Actient historical financi

Slide 10: TESTOPEL Enhances TRT Franchise
TESTOPEL® Enhances TRT Franchise TESTOPEL Product Overview Only FDA approved long-acting implantable testosterone replacement therapy Only form of TRT in U.S. that can restore testosterone for 3-6 months per treatment No boxed warning for secondary exposure to testosterone Implanted subcutaneously i

Slide 11: Edex Enhances Urology Franchise
Edex® Enhances Urology Franchise Edex Product Overview Approved in 1997, Edex is a smooth muscle relaxant and works by dilating arteries in penis to allow blood to flow more easily and create an erection Market leading branded erectile dysfunction option for men who fail/are not candidates for oral

Slide 12: Financially Compelling Transaction
Financially Compelling Transaction Anticipated strong top-line growth over next several years Synergize combined company should be able to generate strong operating cash flow Generates anticipated tax benefit (~$60 MM NPV) which further contributes to improved cash flow (and effectively offsets port

Slide 13: Update on Actient Integration
Update on Actient Integration 12 First step toward expected synergies taken - All Actient employees notified of status – permanent employment, transitional or elimination of position - Transitional employees’ assignments to end August 30 and December 31 Leveraging sales expertise with three sales fo

Slide 14: 2013 Financial Guidance
Total Revenues $325 - 355 $360 – 415 (1) Global Testim Revenues $250 - 265 $210 – 240 XIAFLEX: U.S. Revenues $65 - 75 $55 – 65 Ex-U.S. / Def. Rev $10 - 15 $10 – 15 Total XIAFLEX Revenues $75 - 90 $65 - 80 Total Actient Revenues $85 – 95 (1) R & D Expense (non-GAAP) $45 - 55 S G & A Expense (non-GAAP

Slide 15: Projected 2013 Revenue Growth
Projected 2013 Revenue Growth 2 Mid-point of guidance; Actient 8 months revenues included 1 See Appendix for reconciliation of the pro forma non-GAAP financial measures to the closest GAAP financial measures 15% 27% 14 0 50 100 150 200 250 300 350 400 2011 2012 2013 Actient Auxilium $264.3 ~$387.5 $

Slide 16: A Broader and More Diversified Portfolio
Therapeutic Area Nonclinical Phase I Phase II Phase III Approved Urology Male Hypogonadism Testim 1% Male Hypogonadism TESTOPEL Erectile Dysfunction Edex Erectile Dysfunction Osbon ErecAid Male Hypogonadism Striant Peyronie’s Disease CCH Male Hypogonadism T-gel Orthopedics Dupuytren’s Contracture XI

Slide 17: Peyronie's Disease - A Devastating Disorder
Peyronie’s Disease - A Devastating Disorder Disease Background Potential symptoms1: penile curvature deformity /deviation, pain with erection, penile shortening, indentations, erectile dysfunction, difficulty with sexual intercourse PD - physically and psychologically devastating In literature estim

Slide 18: XIAFLEX IMPRESS Studies - Summary
XIAFLEX IMPRESS Studies - Summary XIAFLEX showed statistically significant improvements in both co-primary endpoints of the IMPRESS I and II Phase III studies Improvement (p-values of 0.0005 and 0.0059) in penile curvature deformity (physical) Improvement (p-values of 0.0451 and 0.0496) in Peyronie’

Slide 19: XIAFLEX 3-D Photographic Evaluation
XIAFLEX 3-D Photographic Evaluation Subject 1106-7852 –Baseline curvature deformity - 45° End of study curvature deformity - 28°(38% Improvement) AUX-CC-802 Photo Sub-Study Subject 38% Improvement 18

Slide 20: Peyronie's Disease Market Opportunity
Peyronie’s Disease Market Opportunity Category Invasive Surgical1 Invasive Non-Surgical1 Non-Invasive No Treatment2,4 Description / Examples Plication, grafting, prosthesis Verapamil injection Vitamin E, potaba, colchicine Patient Counts 1,500 – 2,000 3,500 – 4,500 40,000 – 66,500 20,000 – 47,000 Ur

Slide 21: Peyronie's - Key Potential Success Factors
Peyronie’s- Key Potential Success Factors Define XIAFLEX as Solution to Unmet Medical Need for Serious Condition Optimize Coverage and Mitigate Access Issues Thorough Injection Procedure Training Focused Targeting Activate Product Champions 20

Slide 22: CCH Top-line Day Cellulite Phase Ib Data
CCH Top-line Day 30 Cellulite Phase Ib Data Supports Progression into Phase II XIAFLEX was well-tolerated in the Cellulite Phase Ib 21

Slide 23: Frozen Shoulder – CCH Dose Response in Phase IIa Study
Frozen Shoulder – Statistically Significant CCH Dose Response in Phase IIa Study Both the 0.58 mg(1mL) and 0.58 mg(2mL) cohort demonstrated statistically significant improvement in pain and function over baseline scores vs. the exercise-only group (p<0.05). Treatment-related adverse events with CCH

Slide 24: "New" Auxilium: Near Term Priorities
“New” Auxilium: Near Term Priorities Efficiently integrate Actient Maximize value of current portfolio Stabilize/grow Testim market share & increase unit sales Drive to standard of care in Dupuytren’s for XIAFLEX Grow TESTOPEL, Edex, Osbon ErecAid and Striant use with Urologists Prepare for and succ

Slide 25: Deutsche Bank Conference Corporate Overview and Strategy
Deutsche Bank Conference “Corporate Overview and Strategy” May 29, 2013

Slide 26: Appendix
Appendix

Slide 27: Non-GAAP Financial Measures Notice
This presentation contains pro-forma financial measures that are not consistent with the financial measures that would be reported in financial statements prepared in accordance with generally accepted accounting principles, or GAAP. These non-GAAP financial measures should not be relied upon as an

Slide 28: Reconciliation of GAAP to Non-GAAP Net Income (Loss)
Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) A2 3 Months Ended March 31, 2013 3 Months Ended March 31, 2012 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues 66.2 $ - $ 66.2 $ 73.6 $ - $ 73.6 $ Operating expenses: Cost of goods sold 15.1 (0.0) (a) 15.1 16.6 (0.0) (a)

Slide 29: Reconciliation of GAAP to Non-GAAP Net Income (Loss) Notes
Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) A3 3 Months Ended 3 Months Ended March 31, 2013 March 31, 2012 (a) Costs of goods sold: Employee stock-based compensation (1) (0.0) (0.0) (b) Research and development expenses: Employee stock-based compensation (1) (0.7) (0.6) (c) Selling

Slide 30: Auxilium 1st Quarter 2013 Net Revenue Details
Auxilium 1st Quarter 2013 Net Revenue Details A4 Increase 2013 2012 (Decrease) Testim revenues- Net U.S. product sales $45.3 $57.9 -22% International revenues 0.2 0.8 -78% Total Testim revenues $45.5 $58.7 -23% XIAFLEX revenues- Net U.S. product sales $12.0 $12.6 -5% International revenues 8.8 2.3 2

Slide 31: Actient Financial Information Cautionary Notes
The audited financial information and other financial information of Actient contained in this presentation has not been audited or independently verified by Auxilium or its registered independent public accountants. The financial information of Actient is being provided by Auxilium for information

Slide 32: Actient Audited Revenues – 2010 - 2012
Actient Audited Revenues – 2010 - 2012 $ Millions +250% +96% Source: Actient audited financial statements and supporting ledgers. See slide A5 in the Appendix to this presentation for a detailed explanation of, and cautionary statements regarding, the source of the Actient historical financial data.

Slide 33: Pro Forma As Adjusted 2012 EBITDA
Pro Forma As Adjusted 2012 EBITDA 1 See slide A11 in the Appendix to this presentation for details 2 See slides A15-A16 in the Appendix to this presentation for details 3 Reflects full year run rate synergies expected to be achieved by 2015. The majority of run rate synergies are expected to be achi

Slide 34: 2012 Combined Pro Forma As Adjusted Revenues
2012 Combined Pro Forma As Adjusted Revenues b c a d See slide A5 in the Appendix to this presentation for a detailed explanation of, and cautionary statements regarding, the source of the Actient historical financial data. A8 Auxilium Reported 2012 Revenue 395.3 Less Pfizer Termination Revenue Incl

Slide 35: 2012 Combined Pro Forma Revenues (cont.)
2012 Combined Pro Forma Revenues (cont.) (d) In 2012, Actient adjusted the return reserve for UCB products to reflect a lower return rate based on actual returns experienced. This reduction in the reserve resulted in higher net revenues recorded. Auxilium believes that $1.5 MM of this reduction in t

Slide 36: Auxilium Historical and Pro Forma Financial Performance
Auxilium Historical and Pro Forma Financial Performance $MM $MM $MM $MM 2010 2011 2012 2010 2011 2012 Revenue PF Adj. EBITDA Gross Profit PF Adj. EBITDA less Capex Note: See slides A11-A13 in the Appendix to this presentation for explanation of all adjustments made to audited financial statements of

Slide 37: Auxilium 2012 Pro Forma Financial Data
Auxilium 2012 Pro Forma Financial Data A11 EBITDA EBITDA $ millions Revenue Gross Profit Net Income Adjustments EBITDA CapEx Less CapEx As Reported 395.3 $ 316.9 $ 85.9 $ 8.7 $ 94.6 $ 94.6 $ (a) Eliminate Pfizer Termination (92.0) $ (83.7) $ (83.7) $ (83.7) $ (83.7) $ (b) Eliminate Stock Based Compe

Slide 38: Auxilium 2011 Financial Data
Auxilium 2011 Financial Data A12 EBITDA EBITDA $ millions Revenue Gross Profit Net (Loss) Adjustments EBITDA CapEx Less CapEx As Reported 264.3 $ 208.7 $ (32.9) $ 7.7 $ (25.2) $ (25.2) $ (a) Eliminate Stock Based Compensation 17.3 $ 17.3 $ 17.3 $ (b) Capital Expenditures - $ - $ (6.6) $ (6.6) $ (c)

Slide 39: Actient Historical and Pro Forma Financial Performance
Actient Historical and Pro Forma Financial Performance Revenue $MM PF Adj. EBITDA $MM Gross Profit $MM PF Adj. EBITDA less Capex $MM 2010 2011 2012 2010 2011 2012 2010 2011 2012 2010 2011 2012 Note: See slides A15-A18 in the Appendix to this presentation for explanation of all adjustments made to au

Slide 40: Actient 2012 Pro Forma Financial Data
Actient 2012 Pro Forma Financial Data A15 EBITDA EBITDA $ millions Revenue Gross Profit Net Income Adjustments EBITDA CapEx Less CapEx Per Financial Statements 114.9 $ 85.0 $ (24.2) $ 42.7 $ 18.5 $ 18.5 $ (a) Change in Fair Value of Contingent Consideration - $ 20.3 $ 20.3 $ 20.3 $ (b) TESTOPEL Out

Slide 41: Actient 2012 Pro Forma Financial Data – Cont'd
Actient 2012 Pro Forma Financial Data – Cont’d A16 (g) Adjustment represents capital expenditures per statement of cash flows. (f) Respesents a number of smaller adjustments to Revenues and EBITDA that the Company believes are reasonable to include as a pro forma adjustment and provides investors wi

Slide 42: Actient 2011 Financial Data
Actient 2011 Financial Data A17 EBITDA EBITDA $ millions Revenue Gross Profit Net Income Adjustments EBITDA CapEx Less CapEx Per Financial Statements 58.6 44.3 1.3 $ 14.7 $ 16.0 $ 16.0 $ (a) Change in Fair Value of Contingent Consideration 2.5 $ 2.5 $ 2.5 $ (b) Intangible Asset Impairment 3.2 $ 3.2

Slide 43: Actient 2010 Financial Data
Actient 2010 Financial Data A18 EBITDA EBITDA $ millions Revenue Gross Profit Net (Loss) Adjustments EBITDA CapEx Less CapEx Per Financial Statements 16.7 12.4 (2.8) $ 6.2 $ 3.4 $ 3.4 $ (a) Capital Expenditures - $ - $ (0.1) $ (0.1) $ (b) Adjusted, pro forma non-GAAP 16.7 $ 12.4 $ (2.8) $ 6.2 $ 3.4

Slide 44: Actient's Other Products
Actient’s Other Products Product Therapeutic Area Description (theophylline anhydrous) Respiratory Theophylline is a methylxanthine drug that treats both COPD and asthma Approved in 1983; BC rated generic and not substitutable without physician consent Theo-24 has a narrow therapeutic window with a
Source: SEC EDGAR · 8-K filed May 29, 2013
More decks from Auxilium Pharmaceuticals Inc
Merger or Acquisition (December 2014)20 slides · Dec 3, 2014
Q3 2014 Earnings Presentation26 slides · Nov 5, 2014
Merger or Acquisition (November 2014)15 slides · Nov 5, 2014
Merger or Acquisition (October 2014)15 slides · Oct 15, 2014
Merger or Acquisition (October 2014)10 slides · Oct 10, 2014
Merger or Acquisition (October 2014)16 slides · Oct 9, 2014